The 2-Minute Rule for Brr2-IN-3
Kantarjian et al53 assessed the efficacy and protection of dasatinib, as in comparison with imatinib, for the main-line treatment method of CML-CP. 5 hundred and nineteen sufferers with recently diagnosed CML-CP were randomly assigned to get dasatinib in a dose of one hundred mg at the time daily (259 sufferers) or imatinib in a dose of 400 mg the